Article preview from "The Gray Sheet"- October 31, 2011
FDA is changing the way it vets clinical trial plans to allow firms to start pivotal trials earlier while still ensuring that the study data ultimately supports a pre-market application.
FDA Policy Change Would Make It Easier To Start Pivotal Trials
Article preview from "The Gray Sheet"- October 31, 2011
The agency gave a glimpse into its upcoming draft guidance on clinical trial investigational device exemptions last week at the Regulatory Affairs Professionals Society annual meeting in Indianapolis.
FDA admits it faces a conundrum: Setting the bar for approving an IDE study plan too high could delay the introduction of innovative new products. But setting the bar too low could allow companies to move forward with clinical trials that ultimately cannot support an FDA approval.
The new draft guidance – expected out within the next few months – is meant to strike a balance between speed and prudence.
“We want to try to encourage early study design and development and initiation,” Christy Foreman, director of FDA’s Office of Device Evaluation, said at the RAPS meeting.
About two years ago, FDA implemented a policy of only approving IDEs for pivotal clinical trials that the agency believed would support a marketing application. Previously, the agency approved IDEs even if it had doubts about whether the study would produce the data necessary to support a PMA.
Continued...
To read this article in its entirety, Purchase now as a PDF and receive it immediately via email. Or get it FREE when you subscribe to Medtech Insight Newsletter.
About Medtech Insight
Medtech Insight newsletter provides insights into the technology and market developments (devices, instrumentation, biomaterials, gene therapy, tissue engineering, etc.) impacting a wide range of surgical and non-surgical clinical practices.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512





Comments